Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer

Saatci, Özge; Kaymak, Aysegül; Raza, Umar; G. Ersan, Pelin; Akbulut, Özge; E. Banister, Carolyn; Sikirzhytski, Vitali; Metin Tokat, Ünal; Aykut, Gamze; A. Ansari, Suhail; Tatlı Doğan, Hayriye; Doğan, Mehmet; Jandaghi, Pouria; Işık, Aynur; Gündoğdu, Fatma; Kösemehmetoğlu, Kemal; Dızdar, Ömer; Aksoy, Sercan; Akyol, Aytekin; Üner, Ayşegül; Buckhaults, Phillip; Riazalhosseini, Yasser; Şahin, Özgür

doi:10.1038/s41467-020-16199-4

Public

Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer

Published in Nature Communications • May 15, 2020

Authors:

Özge Saatci

Aysegül Kaymak

Umar Raza

Abstract

Chemoresistance is a major obstacle in triple negative breast cancer (TNBC), the most aggressive breast cancer subtype. Here we identify hypoxia-induced ECM re-modeler, lysyl oxidase (LOX) as a key inducer of chemoresistance by developing chemoresistant TNBC tumors in vivo and characterizing their t...

Subject

Lysyl oxidase

Triple-negative breast cancer

Cancer research

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!